CERS Stock Analysis: Cerus | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 534m USD | 12M Return: 94.7% | US1570851014 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.98M
Qual. Beats: 0
Rev. Trend: 99.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cerus Corporation is a U.S.-based biomedical products company headquartered in Concord, California, specializing in blood safety through its proprietary INTERCEPT Blood System platform. The technology uses a controlled biological replication process to inactivate a broad spectrum of blood-borne pathogens in donated platelets, plasma, and red blood cells intended for transfusion, as well as in pathogen-reduced cryoprecipitate used to treat bleeding associated with fibrinogen deficiency. The system also includes the INTERCEPT Illuminator, an LED-based device used to treat blood components.
The company distributes its platelet and plasma systems through both a direct sales force and third-party distributors, with commercial reach spanning the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and other international markets. Founded in 1991 and renamed Cerus Corporation in 1996, the company trades on NASDAQ under the ticker CERS and is classified within the GICS Health Care Supplies sub-industry, a segment that includes specialized medical device and consumables makers serving transfusion medicine, hospital, and clinical laboratory customers.
- INTERCEPT platelet and plasma sales drive quarterly revenue growth
- Red blood cell system FDA approval expands addressable market
- European hospital adoption accelerates pathogen reduction demand
| Net Income: -6.78m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -2.50 > 1.0 |
| NWC/Revenue: 32.28% < 20% (prev 43.73%; Δ -11.44% < -1%) |
| CFO/TA 0.01 > 3% & CFO 2.42m > Net Income -6.78m |
| Net Debt (32.4m) to EBITDA (2.91m): 11.15 < 3 |
| Current Ratio: 1.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (200.6m) vs 12m ago 4.84% < -2% |
| Gross Margin: 52.05% > 18% (prev 56.09%; Δ -4.04% > 0.5%) |
| Asset Turnover: 105.9% > 50% (prev 90.35%; Δ 15.59% > 0%) |
| Interest Coverage Ratio: 0.16 > 6 (EBIT TTM 1.23m / Interest Expense TTM 7.67m) |
| A: 0.35 (Total Current Assets 157.3m - Total Current Liabilities 85.8m) / Total Assets 205.2m |
| B: -5.29 (Retained Earnings -1.09b / Total Assets 205.2m) |
| C: 0.01 (EBIT TTM 1.23m / Avg Total Assets 209.1m) |
| D: 0.52 (Book Value of Equity 70.0m / Total Liabilities 134.5m) |
| Altman-Z'' = -14.38 = D |
| DSRI: 0.86 (Receivables 31.0m/31.4m, Revenue 221.6m/192.5m) |
| GMI: 1.08 (GM 56.09% / 52.05%) |
| AQI: 1.06 (AQ_t 0.14 / AQ_t-1 0.14) |
| SGI: 1.15 (Revenue 221.6m / 192.5m) |
| TATA: -0.04 (NI -6.78m - CFO 2.42m) / TA 205.2m) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of September 05, 2026, the stock is trading at USD 2.59 with a total of 1,102,510 shares traded. Over the past week, the price has changed by -2.26%, over one month by +18.26%, over three months by -7.17% and over the past year by +94.74%.
Current recommended Stop Loss: 2.30 (which is 11.2% or 1.9 ATR below the current price).
Cerus has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy CERS.
- StrongBuy: 4
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.7 | 80.3% |
P/S = 2.4105
P/B = 7.8424
Revenue TTM = 221.6m USD
EBIT TTM = 1.23m USD
EBITDA TTM = 2.91m USD
Long Term Debt = 34.8m USD (from longTermDebt, last quarter)
Short Term Debt = 33.3m USD (from shortTermDebt, last quarter)
Debt = 88.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 11.9m
Net Debt = 32.4m USD (calculated: Debt 88.7m - CCE 56.3m)
Enterprise Value = 566.5m USD (534.0m + Debt 88.7m - CCE 56.3m)
Interest Coverage Ratio = 0.16 (Ebit TTM 1.23m / Interest Expense TTM 7.67m)
EV/FCF = -309.7x (Enterprise Value 566.5m / FCF TTM -1.83m)
FCF Yield = -0.32% (FCF TTM -1.83m / Enterprise Value 566.5m)
FCF Margin = -0.83% (FCF TTM -1.83m / Revenue TTM 221.6m)
Net Margin = -3.06% (Net Income TTM -6.78m / Revenue TTM 221.6m)
Gross Margin = 52.05% ((Revenue TTM 221.6m - Cost of Revenue TTM 106.2m) / Revenue TTM)
Gross Margin QoQ = 51.41% (prev 51.98%)
Tobins Q-Ratio = 2.76 (Enterprise Value 566.5m / Total Assets 205.2m)
Interest Expense / Debt = 8.65% (Interest Expense 7.67m / Debt 88.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 968k (EBIT 1.23m * (1 - 21.00%))
Current Ratio = 1.83 (Total Current Assets 157.3m / Total Current Liabilities 85.8m)
Debt / Equity = 1.27 (Debt 88.7m / totalStockholderEquity, last quarter 70.0m)
Debt / EBITDA = 11.15 (Net Debt 32.4m / EBITDA 2.91m)
Debt / FCF = -17.72 (negative FCF - burning cash) (Net Debt 32.4m / FCF TTM -1.83m)
Total Stockholder Equity = 65.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.24% (Net Income -6.78m / Total Assets 205.2m)
RoE = -10.31% (Net Income TTM -6.78m / Total Stockholder Equity 65.8m)
RoCE = 1.22% (EBIT 1.23m / Capital Employed (Equity 65.8m + L.T.Debt 34.8m))
RoIC = 0.68% (NOPAT 968k / Invested Capital 141.7m)
WACC = 9.58% (E(534.0m)/V(622.7m) * Re(10.04%) + D(88.7m)/V(622.7m) * Rd(8.65%) * (1-Tc(0.21)))
Discount Rate = 10.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.08 | Cagr: 4.39%
[DCF] Fair Price = unknown (Cash Flow -1.83m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.83 | Revenue CAGR: 14.45% | SUE: -0.21 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.01 | Chg30d=N/A | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.04 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+43.8% | GrowthRev=+19.7%
EPS next Year (2027-12-31): EPS=-0.01 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+88.9% | GrowthRev=+9.4%
[Analyst] Revisions Ratio: +0% (up=0, down=0)